Skip to content

Allphase Pharma Consulting, LLC

A Professional Service Provider for the Pharma Industry

Allphase Pharma Consulting, LLC
Menu

Primary menu

  • CONTACT
  • BLOGS
    • The Viewpoint
    • The News
    • Recent Literature
    • Did you know…?
    • QIDP Antibiotics
  • LEGAL
  • WELCOME

Secondary menu

  • The News
  • The Viewpoint
  • Did you know…?
  • Recent Literature
  • QIDP Antibiotics

Tag Archives: underdosing

Why Did PK/PD Modeling Fail Doripenem in VAP?

Posted on December 24, 2014 by Harald — 2 Comments ↓

When imipenem is dosed at 1 g q8h for serious infections, it is infused over 40-60 min. Its label states that it is indicated for “lower RTI”, an old-fashioned term from the days when bronchitis and pneumonias were still lumped together, CAP was not differentiated from HAP, and HAP and Continue reading Why Did PK/PD Modeling Fail Doripenem in VAP?→

Share this:

  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to print (Opens in new window) Print
  • Click to email a link to a friend (Opens in new window) Email
  • Click to share on WhatsApp (Opens in new window) WhatsApp

Like this:

Like Loading...
Posted in The Viewpoint | Tagged ADME, attainment, bactericidal, Beta-lactam, CAP, Doribax, doripenem, FDA, HAP, imipenem, infusion time, J&J, Monte Carlo simulation, mouse thigh model, NI, NLF, non-inferiority, P. aeruginosa, PBP, pharmacokinetics, PK/PD modeling, Primaxin, randomized controlled trial, RCT, RTI, Shionogi, T>MIC, treatment duration, underdosing, VAP, ventilator-associated pneumonia | 2 Replies

Go back

Your message has been sent

Rating(required)
Warning

Footer Menu

Footer menu

  • CONTACT
  • BLOGS
  • LEGAL
  • WELCOME
  • Email
Copyright © 2026 Allphase Pharma Consulting, LLC. All Rights Reserved.
Theme: Catch Box by Catch Themes
Scroll Up
%d